The convergence of AI and biotechnology is reshaping both the promise and the peril of biological research, potentially increasing beneficial capabilities to achieve new therapeutics faster while also introducing new risks that nefarious actors could misuse of biology. Scientists have long considered and taken action to mitigate the dual use risks of biological materials. Recombinant DNA technologies increased the urgency of action. Now, the advent of artificial intelligence, in combination with more sophisticated genetic read and write capabilities necessitates rethinking of the moral obligations of scientists and policy makers. This session will describe the new types of risks enabled by combined data and biological technologies and discuss proposals for effective governance.

Event Information:

Free and open to the public; registration required. For more information, please visit the event webpage.

Hosted by the Center for ELSI Resources and Analysis at Columbia University as part of the ELSI Friday Forum series.